Pall Corporation Launches Ready-to-Use, Scalable Laboratory Chromatography Columns

Pall Corporation Launches Ready-to-Use, Scalable Laboratory Chromatography Columns
New 5 mL Prepacked Columns For Protein Purification Reduce Processing Costs, Save Time, Ensure Consistent Performance

PORT WASHINGTON, N.Y., January 07, 2010 - Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, announces the launch of 5 mL PRC prepacked chromatography columns to deliver faster and more consistent protein purification processing. Pall's PRC prepacked columns for ion exchange and mixed-mode chromatography lower processing costs and save laboratory time by reducing inconsistencies associated with manually packed columns.

PRC columns are available in a wide range of separation media to support applications including native and recombinant proteins, plasmids, vaccines, monoclonal and polyclonal antibodies, and plasma derivatives.

The ready-to-use columns provide a direct connect to existing lab-scale chromatography systems. The columns are efficient (greater than or equal to 2,500 plates per meter) and their performance remains consistent throughout a process.

Pall 5 mL PRC columns are available prepacked with Pall's new Q and S HyperCelTM ion exchange chemistries which feature excellent flow properties and high dynamic binding capacity at short residence time. The columns also support the unique selectivities of Pall's MEP, HEA, and PPA HyperCel mixed-mode sorbents.

"Pall columns allow researchers and process developers to quickly and easily evaluate different sorbents early in the drug development process so they can obtain necessary scale-up data," said David Lescinski, vice president, chromatography, Pall Life Sciences. "The 1 and 5 mL columns, along with Pall's comprehensive range of sorbents, provide complete solutions from development to commercial-scale production."

The new 5 mL PRC columns are the latest additions to a line that includes 1 mL prepacked columns. These development-scale columns provide rapid selectivity screening of the desired chemistry. Simple optimization can be achieved by coupling two columns in series to replicate production-process typical bed heights. Additional scale-up can be achieved with minimal re-optimization by packing Pall LRC empty glass columns.

Prepacked chromatography columns are available through Pall Life Sciences and can be ordered by phone at 1-800-717-7255 in the U.S. or +41 (0)26 350 53 00 in Europe. For a complete listing of international offices visit Pall online at www.pall.com/contact.

Note to Editors: A high-resolution photograph of Pall's PRC prepacked columns are available for download at www.pall.com/news.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical, hospital and transfusion medicine, energy and alternative energy, electronics, municipal and industrial water, aerospace, transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The Company's engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees servicing customers worldwide. Pall has been named a top "green company" by Newsweek magazine. To see how Pall is helping enable a greener and more sustainable future, visit www.pall.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6135260&lang=en

Pall Life Sciences
Carol Flint - VP Marketing Communications
Phone: 734-913-6432
For photos, please email: [email protected]
www.pall.com

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.